MarketCap
Facebook
X
TelegramAnnual report 2024
added 03-21-2026
Tiziana Life Sciences PLC Retained Earnings 2011-2026 | TLSA
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Tiziana Life Sciences PLC
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -84.6 M | -43.1 M | -39.9 M | -29.8 M | 11 M | -12.2 M | -3.59 M | -21.4 M | -21.1 M | -20.5 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 11 M | -84.6 M | -26.5 M |
Quarterly Retained Earnings Tiziana Life Sciences PLC
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -108 M | - | - | - | -84.6 M | - | - | - | -60 M | - | - | - | -50.7 M | - | - | - | -42.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -42.6 M | -108 M | -69.2 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Altimmune
ALT
|
-649 M | $ 3.41 | 2.1 % | $ 300 M |  USA |
 |
Amgen
AMGN
|
-25.1 B | $ 350.17 | 0.68 % | $ 188 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
667 M | $ 19.57 | 0.36 % | $ 915 M | USA |
 |
I-Mab
IMAB
|
-8.33 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-405 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
-611 M | $ 217.82 | -1.83 % | $ 5 B |  Danmark |
 |
Autolus Therapeutics plc
AUTL
|
-1.1 B | $ 1.4 | 1.82 % | $ 357 M |  Britain |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
Aytu BioScience
AYTU
|
-334 M | $ 2.64 | 1.15 % | $ 16.6 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-308 M | - | - | $ 26.5 M | USA |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
-335 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-131 M | - | -10.17 % | $ 12.2 K | USA |
 |
Benitec Biopharma
BNTC
|
-228 M | $ 11.0 | 0.18 % | $ 453 M | USA |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
-301 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
-351 M | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
-221 M | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
Avenue Therapeutics
ATXI
|
-103 M | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-1.07 B | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-141 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-197 M | - | -9.65 % | $ 45.9 M | USA |
 |
Coherus BioSciences
CHRS
|
-1.38 B | $ 1.58 | 3.62 % | $ 185 M | USA |
 |
Cellectis S.A.
CLLS
|
-506 M | $ 3.35 | 0.3 % | $ 116 M | France |
 |
Ayala Pharmaceuticals
AYLA
|
-149 M | - | - | $ 7.46 M |  Israel |
 |
Cullinan Management
CGEM
|
-588 M | $ 12.83 | 0.71 % | $ 773 M | USA |
 |
Atreca
BCEL
|
-457 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
-256 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-8.32 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
-491 M | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
-685 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-617 M | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
-252 M | - | -74.18 % | $ 955 K | USA |
 |
CorMedix
CRMD
|
-177 M | $ 6.29 | 0.64 % | $ 453 K | USA |
 |
CytomX Therapeutics
CTMX
|
-712 M | $ 4.41 | -1.01 % | $ 608 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
-371 M | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
-2.88 B | - | -7.23 % | $ 13 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-1.13 B | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-1.06 B | - | - | $ 867 M | Germany |
 |
Compugen Ltd.
CGEN
|
-453 M | $ 2.12 | 1.2 % | $ 198 M | Israel |
 |
Denali Therapeutics
DNLI
|
-1.54 B | $ 20.92 | 3.69 % | $ 3.44 B | USA |
 |
Dyadic International
DYAI
|
-80.3 M | $ 0.89 | -5.85 % | $ 25.6 M | USA |
 |
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-1.28 B | $ 4.26 | 0.47 % | $ 707 M | Canada |
 |
Akouos
AKUS
|
-168 M | - | 0.23 % | $ 488 M | USA |